RxDoctor Payments Data

Errol Williams, MD

Cardiovascular Disease · Ontario, OHNPI 1366456519

Payments from drug & device makers

$286in general payments, 2019–2025

Across 10 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$140
  • Bardy Diagnostics, Inc.$60
  • Johnson & Johnson$25
  • Pfizer$18
  • Amarin Pharma, Inc.$14
  • Hologic Sales And Service, LLC$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$17260%
  • Education$11440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca4$140
Bardy Diagnostics, Inc.1$60
Johnson & Johnson1$25
Pfizer1$18
Amarin Pharma, Inc.1$14
Hologic Sales And Service, LLC1$14
Amgen1$14

How this compares

$286 in reported general payments places this provider in the 20th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$90,492
Medicare patients
639
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$313,806
XareltoRivaroxaban72$77,984
Repatha SureclickEvolocumab44$40,398
EntrestoSacubitril/Valsartan17$33,999
BrilintaTicagrelor19$13,604
Ranolazine ErRanolazine46$7,415
VascepaIcosapent Ethyl19$5,595
Metoprolol Succinate360$5,541
Nadolol12$4,670
Digoxin175$3,290
Losartan Potassium226$2,004
Hydralazine Hcl175$1,992
Potassium Chloride120$1,902
Isosorbide Mononitrate ErIsosorbide Mononitrate129$1,871
Omega-3 Acid Ethyl Esters22$1,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$313,806236 claims
Johnson & JohnsonXarelto$25$77,98472 claims
AstraZenecaBrilinta$140$13,60419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Ontario

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →